Medindia

X

First CyberKnife in Belgium to be Installed at Leading University Hospital

Tuesday, December 15, 2009 Cancer News J E 4
Advertisement


SUNNYVALE, Calif., Dec. 14 Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the first CyberKnife® Robotic Radiosurgery System in Belgium will be installed at the University Hospital of Liege.

The University Hospital in Liege, a 1,000-bed hospital, is one of the largest hospitals in Euregio, a cross-country region of 18 million inhabitants.

"With a full range of cancer treatments, University Hospital of Liege is delivering on its promise to offer comprehensive, state-of-the-art cancer care to patients across Belgium," said Professor Philippe Coucke, Head of the Radiation Oncology Department, University Hospital of Liege. "Because of its accuracy and non-invasive nature, the CyberKnife System can offer an alternative to patients who may not be able to tolerate other cancer treatments or who have medically inoperable tumors."

According to the International Agency for Research on Cancer, the total number of new cases of cancer in Europe has increased by approximately 300,000 since 2004. With an estimated 3.2 million new cases and 1.7 million deaths each year, cancer remains an important public health issue in Europe. The situation described by the Belgian Cancer Registry is similar, with 57,185 new cancer cases reported in 2005.

"We are extremely excited to see the benefits of whole body radiosurgery expand into Belgium," said Frederic Sottilini, General Manager, Accuray EIMEA (Europe, India, Middle East and Africa). "This purchase paves the way for greater patient access to CyberKnife radiosurgery, thereby providing patients an additional treatment option that can improve their quality of life."

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to treatment options and particular patient treatments are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2009 fiscal year, our Form 10-Q filed on November 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Lilly Declares First-Quarter 2010 Dividend
S
University HealthSystem Consortium Offers Value An...